Trial Profile
Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms 358
- 16 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 26 Jan 2023 Planned End Date changed from 1 Oct 2025 to 1 Oct 2026.
- 26 Jan 2023 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2024.